Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

HIV Drug Linked to Lower Bone Mass in Newborns

Study shows tenofovir lowers mineral content

Infants exposed in the womb to the anti-HIV drug tenofovir disoproxil fumarate during the expectant mothers’ third trimester may have lower bone mineral content than those exposed to other anti-HIV drugs as well as those who were not exposed to the drug, according to a National Institutes of Health (NIH) study of 143 infants. Of the participants, 74 were exposed to tenofovir in the uterus while 69 were given other anti-HIV drugs. Researchers found:

• Tenofovir-exposed newborns did not differ from unexposed newborns on mean gestational age or mean length or weight.

• The mean bone mineral content of tenofovir-exposed infants was 12% lower than for unexposed infants.

• The adjusted mean bone mineral content was 5.3 g lower in the tenofovir-exposed infants.

Citation: Siberry GK, Jacobson DL, Kalkwarf HJ, et al. Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy. Clin Infect Dis. 2015;61(6): 996-1003. doi: 10.1093/cid/civ437.